Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

[Chemotherapy in prostatic carcinoma]

G Pérez Manga¹, J A Arranz Arija, R García Gómez

¹Servicio de Oncología Médica, Hospital General Gregorio Marañón, Madrid, España.

Archivos Espanoles De Urologia

|March 1, 1993

Summary

Prostate cancer chemotherapy offers limited response rates and short durations, with no clear survival benefit. Combined chemo-hormone therapy may offer slight improvements, but further research is needed.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Prognostic factors and oncological outcomes after trimodality bladder-preserving therapy for muscle-invasive bladder cancer: A multicenter real-world study.

Actas urologicas espanolas·2026

Same author

Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same author

Avelumab plus sacituzumab govitecan versus avelumab monotherapy as first-line maintenance treatment in patients with advanced urothelial carcinoma: JAVELIN Bladder Medley interim analysis.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Same author

Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Same author

Effect of adjuvant chemotherapy in locally advanced urothelial carcinoma of the bladder treated with cystectomy.

Actas urologicas espanolas·2019

Same author

Correction to: Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling.

Breast cancer research and treatment·2018

Area of Science:

Oncology
Medical Chemistry

Context:

Prostate carcinoma treatment has involved various chemotherapy regimens, including monochemotherapy, polychemotherapy, intraarterial chemotherapy, and combined chemo-hormone therapy.
Evaluating chemotherapy efficacy in prostate cancer is challenging due to small patient cohorts and varied response assessment criteria.

Purpose:

To review the efficacy and limitations of current chemotherapy treatments for prostate carcinoma.
To assess the impact of different chemotherapy modalities and combinations on treatment response and survivorship.

Summary:

Monochemotherapy and polychemotherapy show response rates below 20% and 20% respectively, with short response durations.
No definitive evidence shows chemotherapy improves overall survivorship compared to symptomatic treatment, though combined chemo-hormone therapy might offer slight benefits.

Related Experiment Videos

Adriamycin, fluorouracil, and cyclophosphamide are identified as effective cytostatic agents; growth factor antagonists present new therapeutic avenues requiring further study.

Impact:

Current chemotherapy regimens for prostate cancer have limited efficacy and do not clearly improve survival rates.
Combined chemo-hormone therapy and emerging growth factor antagonists show potential but require further investigation for definitive value.
The lack of a standard treatment highlights the need for improved therapeutic strategies in prostate carcinoma management.